NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
The group is keeping faith with the novel target KLK2.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
